Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Aiyin Liao"'
Autor:
Stuart Ellison, Aiyin Liao, Hélène F.E. Gleitz, Helen Parker, Laura Booth, John Robinson, Shaun Wood, Jessica Taylor, Rebecca Holley, Brian W. Bigger
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 31, Iss , Pp 101127- (2023)
Mucopolysaccharidosis type II (MPSII) is a pediatric lysosomal storage disease caused by deficiencies in the IDS (iduronate-2-sulfatase) gene resulting in accumulation of glycosaminoglycans, multisystem disease, and profound neurodegeneration in seve
Externí odkaz:
https://doaj.org/article/9b7c441d02a944129089fa20c2a74363
Autor:
Helen Parker, Stuart M Ellison, Rebecca J Holley, Claire O'Leary, Aiyin Liao, Jalal Asadi, Emily Glover, Arunabha Ghosh, Simon Jones, Fiona L Wilkinson, David Brough, Emmanuel Pinteaux, Hervé Boutin, Brian W Bigger
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 3, Pp 1-19 (2020)
Abstract Mucopolysaccharidosis IIIA is a neuronopathic lysosomal storage disease, characterised by heparan sulphate and other substrates accumulating in the brain. Patients develop behavioural disturbances and cognitive decline, a possible consequenc
Externí odkaz:
https://doaj.org/article/860e4ff997044c5bbd042e03d9871bf4
Autor:
Stuart M. Ellison, Aiyin Liao, Shaun Wood, Jessica Taylor, Amir Saam Youshani, Sam Rowlston, Helen Parker, Myriam Armant, Alessandra Biffi, Lucas Chan, Farzin Farzaneh, Rob Wynn, Simon A. Jones, Paul Heal, H. Bobby Gaspar, Brian W. Bigger
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss , Pp 399-413 (2019)
Hematopoietic stem cell gene therapy is a promising therapeutic strategy for the treatment of neurological disorders, since transplanted gene-corrected cells can traffic to the brain, bypassing the blood-brain barrier, to deliver therapeutic protein
Externí odkaz:
https://doaj.org/article/600b11bc8c0349f19c29928a25f66440
Autor:
Arunabha Ghosh, Aiyin Liao, Claire O’Leary, Jean Mercer, Karen Tylee, Anu Goenka, Rebecca Holley, Simon A. Jones, Brian W. Bigger
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss , Pp 321-333 (2019)
Enzyme replacement therapy with laronidase is an established treatment for Mucopolysaccharidosis type I (MPS I), but its efficacy may be limited by the development of anti-drug antibodies, which inhibit cellular uptake of the enzyme. In a related dis
Externí odkaz:
https://doaj.org/article/d5c701be64524d9f9189e7ff9e967ff6
Autor:
A. Saam Youshani, Samuel Rowlston, Claire O’Leary, Gabriella Forte, Helen Parker, Aiyin Liao, Brian Telfer, Kaye Williams, Ian D. Kamaly-Asl, Brian W. Bigger
Publikováno v:
Journal of Neuroinflammation, Vol 16, Iss 1, Pp 1-14 (2019)
Abstract Background Chimeric mouse models generated via adoptive bone marrow transfer are the foundation for immune cell tracking in neuroinflammation. Chimeras that exhibit low chimerism levels, blood-brain barrier disruption and pro-inflammatory ef
Externí odkaz:
https://doaj.org/article/24b3db9776604feebdfec27f8592cf84
Autor:
Fiona L Wilkinson, Rebecca J Holley, Kia J Langford-Smith, Soumya Badrinath, Aiyin Liao, Alex Langford-Smith, Jonathan D Cooper, Simon A Jones, J Ed Wraith, Rob F Wynn, Catherine L R Merry, Brian W Bigger
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e35787 (2012)
Mucopolysaccharide diseases (MPS) are caused by deficiency of glycosaminoglycan (GAG) degrading enzymes, leading to GAG accumulation. Neurodegenerative MPS diseases exhibit cognitive decline, behavioural problems and shortened lifespan. We have chara
Externí odkaz:
https://doaj.org/article/795f2465ae6c40f69f556671f049448c
Autor:
Shaun Roger Wood, Ahsan Chaudrhy, Stuart Ellison, Rachel Searle, Constance Burgod, Ghazala Tehseen, Gabriella Forte, Claire O'Leary, Helene F Gleitz, Aiyin Liao, James Cook, Rebecca Jane Holley, Brian Bigger
Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disease caused by a mutation in the IDS gene, resulting in deficiency of the enzyme iduronate-2-sulfatase (IDS) causing heparan sulfate (HS) and dermatan sulfate (DS) accumulation in all ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde2ec6ef8b048fb8cd4a96350c9ba4e
http://hdl.handle.net/10044/1/104683
http://hdl.handle.net/10044/1/104683
Autor:
Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Caetano-Silva, Winston Vetharoy, Ian Kirby, Francesca Zammarchi, Karin Havenith, Patrick H van Berkel, Claire Booth, H Bobby Gaspar, Adrian J. Thrasher, Kerry Chester, Persis J Amrolia
Publikováno v:
Blood. 140:10211-10212
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95d667aa5b110d1da212c5968f8fd258
https://doi.org/10.1182/blood-2022-162390
https://doi.org/10.1182/blood-2022-162390
Autor:
Shaun R. Wood, Ahsan Chaudrhy, Stuart M. Ellison, Rachel Searle, Gabriella Forte, Claire O'Leary, Helene Gleitz, Aiyin Liao, Rebecca Holley, Brian Bigger
Publikováno v:
Molecular Genetics and Metabolism. 138:107361
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::998fdb7b147aae225c16ac3b58817457
https://doi.org/10.1016/j.ymgme.2022.107361
https://doi.org/10.1016/j.ymgme.2022.107361
Autor:
Aiyin Liao, Anu Goenka, Simon Jones, Brian W. Bigger, Arunabha Ghosh, Claire O'Leary, Karen Tylee, Rebecca J. Holley, Jean Mercer
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss, Pp 321-333 (2019)
Molecular Therapy. Methods & Clinical Development
Ghosh, A, Liao, A, O'Leary, C, Mercer, J, Tylee, K, Goenka, A, Holley, R, Jones, S A & Bigger, B W 2019, ' Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I ', Molecular Therapy-Methods and Clinical Development, vol. 13, pp. 321-333 . https://doi.org/10.1016/j.omtm.2019.02.007
Molecular Therapy. Methods & Clinical Development
Ghosh, A, Liao, A, O'Leary, C, Mercer, J, Tylee, K, Goenka, A, Holley, R, Jones, S A & Bigger, B W 2019, ' Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I ', Molecular Therapy-Methods and Clinical Development, vol. 13, pp. 321-333 . https://doi.org/10.1016/j.omtm.2019.02.007
Enzyme replacement therapy with laronidase is an established treatment for Mucopolysaccharidosis type I (MPS I), but its efficacy may be limited by the development of anti-drug antibodies, which inhibit cellular uptake of the enzyme. In a related dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7fa2a8451b9998558df1d9a781de0b1
http://www.sciencedirect.com/science/article/pii/S2329050119300245
http://www.sciencedirect.com/science/article/pii/S2329050119300245